IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$8.09 USD
-0.40 (-4.71%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $8.08 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 41 - 60 ( 87 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Collaboration Inked; 2021 Financial Results; Modulating PT to $59
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; SNY Collaboration for Agonist IO & Autoimmune Targets Announced
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Initial IGM-6268 Clinical Results in COVID-19 Expected This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Although Early, IGMS-2323 Results Appear to Underwhelm; Lowering PT to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-2323 ORR Snapshot Modest, but Higher Doses Confound Picture
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Updated IGM-2323 Results at ASH; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Updates Across Broadening Pipeline;Upgrading to OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; IGM-2323 Dose Escalation Complete; Data for Two Programs Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-6268 Entering Clinic in 3Q21 for COVID-19; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Licensing Deal for IgM Antibody for COVD-19; Clinical Entry Expected in Q3:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Correction: Q1 Financials; Many Hands Make Light Work - Programs Remain on Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Data Could Derisk IGM-2323; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R